510(k) device
Embrace
Empatica S.r.l. · Physiological Signal Based Seizure Monitoring System (POS, Class II) · First FDA decision Jan 26, 2018, newest Dec 20, 2018Epilepsy
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
Breakthrough-designated
Device trials
17
Naming "Embrace"
MAUDE reports
27
Brand "Embrace", since 2015
PubMed studies
9,486
Mentioning "Embrace"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Embrace
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
- Embrace510(k)
K181861 · Decided Dec 20, 2018 · 161 days after receipt
Device type: Physiological Signal Based Seizure Monitoring System (POS) · Neurology & Neurosurgery
- EmbraceBreakthrough510(k)
K172935 · Decided Jan 26, 2018 · 122 days after receipt
Device type: Physiological Signal Based Seizure Monitoring System (POS) · Neurology & Neurosurgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Embrace", any status and sponsor, newest update first.
- RASSURE - Virtual Reality to Soothe, Secure, Simulate Uses, and Successfully Complete the ExaminationPivotal-lookingNot yet recruiting
Pôle Saint HélierAcademic, hospital or other
NCT07949097 · 100 participants (planned) · Start Dec 1, 2026 · Primary completion Mar 30, 2028
Device: Embrace Plus wristband; PREPASOINS_VR virtual reality headset and 1 more · For: Psychological Disability; Mental Disability
Sites: Rennes, France; Thorigné-Fouillard, France
Dartmouth-Hitchcock Medical CenterAcademic, hospital or other
NCT06701461 · 0 participants · Start Aug 2026 · Primary completion Sep 2026
Device: Electrodermal Activity signal · For: Osteo Arthritis Knee
Sites: Lebanon, New Hampshire
Cortex NeurovascularNot on our public-company list
NCT07313800 · 0 participants · Start Mar 1, 2028 · Primary completion Mar 1, 2030
Device: TEMMA Endovascular Treatment · For: Migraine Disorders; Refractory Migraine; Chronic Migraine
Sites: Tacoma, Washington
14 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Embrace", and for the whole product code for context.
This brand
27 reports: 13 malfunction, 14 injury, 0 death
Whole product code POS
4 reports: 2 malfunction, 2 injury, 0 death
Newest reports for this brand
3006721341-2026-00013 · Received Jun 23, 2026 · Event dated May 28, 2026
Device type: Prosthesis, Shoulder, Semi-Constrained, Metal/Polymer + Additive, Cemented (PAO)
Device problem as coded: Improper or Incorrect Procedure or Method
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- EMBRACE PRO BLOOD GLUCOSE METERMalfunction
MW5189422 · Received Jun 15, 2026 · Event dated May 11, 2026
Device type: System, Test, Blood Glucose, Over The Counter (NBW)
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
3004371426-2026-00045 · Received Jun 12, 2026 · Event dated May 14, 2026
Device type: Prosthesis, Shoulder, Semi-Constrained, Metal/Polymer + Additive, Cemented (PAO)
Device problem as coded: Device Dislodged or Dislocated
Patient problem as coded: Insufficient Information
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-0159-2024 · Started Jul 13, 2023 · Posted by FDA Oct 24, 2023
Reason given: May have a battery life lasting less than the full 48 hours, requiring the device to be charged more frequently.
Cause as FDA categorized it: Device Design · Device type: Physiological Signal Based Seizure Monitoring System (POS)
Published research
The most relevant PubMed records for "Embrace"[tiab]. The summary above synthesizes these.
- Embrace Progress.
Bradley KM, McGowan DR, Gleeson FV, et al. · J Nucl Med · 2018Letter, Comment
- Embrace uncertainty.
Córdova FA · Science · 2016
- Embrace Uncertainty.
de Koning JJ, Noordhof DA · Int J Sports Physiol Perform · 2019Editorial
- Embrace compassion.
Larsen J · Science · 2023
- Instant Oncology: EMBRACE-I.
Wang L · Clin Oncol (R Coll Radiol) · 2023Editorial
- Should We Embrace Our Robot Overlords?
Hughes H, Patlas MN · Can Assoc Radiol J · 2024Editorial
- [The EMBRACE study].
Gaita F, Anselmino M, Sessa M · G Ital Cardiol (Rome) · 2015
- Embrace the fat when getting old.
Adlung L, Amit I, Elinav E · Aging (Albany NY) · 2019Editorial, Research Support, Non-U.S. Gov't
- Embrace the Learn.
Fraser D · Neonatal Netw · 2021Editorial
- Embrace MBRRACE?
Drug Ther Bull · 2014Editorial
- Should we embrace the term 'preaddiction'?
Boness CL, Kataria K, Morris J · Neuropsychopharmacology · 2024
- Embrace Nursing Science, Empower Healthier Lives.
Tsai SY · J Nurs Res · 2023Editorial
Other devices of this type
Also filed under product code POS.
- EpiMonitorEmpatica S.r.l. · 510(k) 2025
- SPEAC SystemBrain Sentinel, Inc. · 510(k) 2021
- Nelli (Version 7.11)Neuro Event Labs OY · 510(k) 2025
- NightWatch+ USLivassured BV · 510(k) 2025
- EpiWatch Monitoring SystemEpiwatch, Inc. · 510(k) 2025
- CompanionLgch, Inc. · De Novo 2017
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.